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MaOBJECTIVES This study sought to investigate acute kidney injury (AKI) following carotid artery stenting (CAS).
BACKGROUND Few data exist on AKI following CAS.
METHODS This study evaluated 126 chronic kidney disease (CKD) patients who underwent CAS. The risk for contrast-
induced AKI was deﬁned by the Mehran score. Hemodynamic depression (i.e., periprocedural systolic blood pressure
<90 mm Hg or heart rate <60 beats/min), AKI (i.e., an increase of $0.3 mg/dl in the serum creatinine concentration
at 48 h), and 30-day major adverse events (including death, stroke, and acute myocardial infarction) were assessed.
RESULTS AKI occurred in 26 patients (21%). Although baseline kidney function and contrast volume were similar in the
AKI group and the non-AKI group, the risk score was higher (10  3 vs. 8  3; p ¼ 0.032), and hemodynamic depression
(mostly due to hypotension) (65.5% vs. 35%; p ¼ 0.005) was more common in the AKI group. The threshold of
hemodynamic depression duration for AKI development was 2.5 min (sensitivity 54%, speciﬁcity 82%). Independent
predictors of AKI were hemodynamic depression (odds ratio [OR]: 4.01; 95% conﬁdence interval [CI]: 1.07 to 15.03;
p ¼ 0.009), risk score (OR: 1.29; 95% CI: 1.03 to 1.60; p ¼ 0.024), and male sex (OR: 6.07; 95% CI: 1.18 to 31.08;
p ¼ 0.021). Independent predictors of 30-day major adverse events that occurred more often in the AKI group (19.5% vs.
7%; p ¼ 0.058) were AKI (HR: 4.83; 95% CI: 1.10 to 21.24; p ¼ 0.037) and hemodynamic depression (HR: 5.58; 95% CI:
1.10 to 28.31; p ¼ 0.038).
CONCLUSIONS AKI in CKD patients undergoing CAS is mostly due to hemodynamic depression and is associated with a
higher 30-day major adverse events rate. (J Am Coll Cardiol Intv 2015;8:1506–14) © 2015 by the American College of
Cardiology Foundation.C hronic kidney disease (CKD) has been asso-ciated with increased morbidity and mortal-ity after coronary revascularization (1). In
contrast, there are only limited and conﬂicting data
on the impact of CKD in patients undergoing carotid
revascularization (2,3). Although some data support
the concept that CKD represents an independent pre-
dictor of unfavorable outcome even following carotid
artery stenting (CAS) (3–6), others refute this associ-
ation (2,7). A potential reason of these conﬂicting re-
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following CAS may occur because of iodinated
contrast media (CM) and hemodynamic depression.
These 2 factors are not mutually exclusive but
may act together in causing AKI. CM is a well-
recognized cause of AKI. Hemodynamic depression,
which occurs in 7% to 42% of patients undergoing
coronary artery stenting (CAS) (9–12), might alsof Cardiology, Clinica Mediterranea, Naples, Italy;
itute of Genetic and Biomedical Research, National
ter, Rozzano, Milan, Italy. The authors have reported
close.
, 2015, accepted May 22, 2015.
AB BR E V I A T I O N S
AND ACRONYM S
AKI = acute kidney injury
CAS = carotid artery stenting
CI = conﬁdence interval(s)
CKD = chronic kidney disease
CM = contrast media
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1507have an important role in the pathogenesis of
AKI (13).
In the present study on CKD patients undergoing
CAS, we assessed the following: 1) the rate of AKI; 2)
the role of CM and hemodynamic depression in the
pathogenesis of AKI; and 3) the correlation between
AKI and 30-day major adverse events (MAE)—death,
stroke, and myocardial infarction.SEE PAGE 1515
eGFR = estimated glomerular
ﬁltration rate
IQR = interquartile range
MAE = major adverse event(s)
NAC = N-acetylcysteine
OR = odds ratio(s)
sCr = serum creatinineMETHODS
PATIENT POPULATION. CKDpatients (with estimated
glomerular ﬁltration rate [eGFR] #60 ml/min/1.73 m2)
scheduled for CAS at the Clinica Mediterranea from
February 2, 2009 to September 17, 2013 were screened.
Exclusion criteria were recent (#48 h) administration
of iodinated CM, dialysis, contraindication to aspirin
and thienopyridines, and current enrollment in any
other study. All patients who met the inclusion/
exclusion criteria and signed an informed consent
were included into the study. Patients were classiﬁed
as symptomatic if they had experienced a recent
transient ischemic attack, stroke, or transient monoc-
ular blindness ipsilateral to the study artery in the
preceding 180 days before randomization. Otherwise,
they were classiﬁed as asymptomatic.
STENTING TECHNIQUE. All patients were considered
to be suitable for CAS, according to 2011 recommen-
dations (14). All stenting procedures were performed
according to the recommendations and without the
induction of general anesthesia and/or sedation. A
protection device was used in all instances. Balloon
pre-dilation was performed only in case of failure of
direct stenting. Self-expanding stents were used in all
instances. Stents were classiﬁed according to alloy: 1)
braided Elgiloy (Carotid Wallstent, Boston Scientiﬁc,
Natick, Massachusetts); and 2) nitinol stents (X-Act
and Acculink [Abbott Vascular Devices, Redwood
City, California]; Precise [Cordis, Miami Lakes, Flor-
ida]; Crystallo Ideale [Medtronic Inc., Minneapolis,
Minnesota]; Protegè (ev3, Plymouth, Minnesota);
Sinus Carotid RX (Optimed, Ettlingen, Germany).
Furthermore, stents were divided according to cell
design: 1) closed cells: Carotid Wallstent and X-Act; 2)
open cells: Precise and Protegè; and 3) hybrid: Crys-
tallo Ideale, and Sinus Carotid RX. Balloon post-
dilation was routinely performed with a 5.0-mm
balloon. All patients received atropine (1.0 mg intra-
venously) before balloon post-dilation to minimize
hemodynamic depression. Unfractionated heparin
(10,000 IU) was administered intravenously at the
beginning of the procedure. All patients receivedaspirin (100 mg/day) and clopidogrel pre-load
(600 mg) 24 h before the procedure. After the
procedure, clopidogrel was continued for at
least 1 month, whereas aspirin was continued
for life. The severity of stenosis was quanti-
ﬁed using the NASCET (North American
Symptomatic Carotid Endarterectomy Trial)
criteria (15). A baseline cranial computed to-
mogram was obtained in all patients. Neuro-
logic evaluations were performed every 6 h or
more frequently if the patient experienced
any clinical deterioration.
We measured sCr the day before the pro-
cedure and at 24 h, 48 h, and 1 week after CM
administration. Additional measurements
were performed in case of a deterioration of
baseline renal function. We calculated eGFR by
applying the Modiﬁcation of Diet in Renal Disease
formula (16). CKD was deﬁned as an eGFR <60 ml/
min/1.73 m2. The risk for predicting contrast-induced
AKI was calculated according to Mehran et al. (17).
Heart rate and blood pressure were assessed
continuously during the procedure. After the pro-
cedure, patients were transferred to the post-
interventional care unit, where heart rate and blood
pressure were monitored continuously. Hemody-
namic depression was deﬁned as symptomatic or
asymptomatic hypotension (systolic blood pres-
sure <90 mmHg) or bradycardia (heart rate <60 beats/
min) at any time during or within the ﬁrst 24 h after
stent deployment (9,10,12,18). Treatment includes
intravenous ﬂuid boluses ($500 ml), followed by the
addition of dopamine (starting from 5 mg/kg/min).
Patients who required continuous vasopressor infu-
sion after CAS were considered to have persistent
hemodynamic depression (9).
Contrast-induced AKI prophylaxis strategies were
as follows: 1) in patients with eGFR 30 to 59 ml/min/
1.73 m2, hydration with sodium bicarbonate solution
(154 mEq/l) plus high dose of N-acetylcysteine (NAC)
(19); or 2) in patients with eGFR <30 ml/min/1.73 m2,
hydration with normal saline plus NAC controlled
by the RenalGuard system (PLC Medical Systems,
Franklin, Massachusetts) (19). Although the results
on the use of NAC are conﬂicting, experimental
studies demonstrated that NAC exerts its antioxidant
properties preventing kidney cell death by inhibiting
oxygen free radical production and thus stress
kinases and apoptosis activation upon CM exposure
(20). Iodixanol (Visipaque, GE Healthcare, Princeton,
New Jersey) was used in all patients. In order to
identify patients receiving a high-contrast load, the
following weight- and creatinine-adjusted maximum
contrast dose formula was used: 5  kilograms of body
TABLE 1 Clinical Characteristics of the Global Population and of Patients With Versus
Those Without AKI
Global Population
(n ¼ 126)
AKI Group
(n ¼ 26)
Non-AKI Group
(n ¼ 100) p Value
Age, yrs 76  7 77  5 75  7 0.23
Male 95 (75.5) 22 (85) 73 (73) 0.059
Active smokers 15 (12) 6 (23) 9 (9) 0.085
Weight, kg 76  13 75  9 76  10 0.54
Height, m 1.65  0.8 1.66  0.7 1.65  087 0.25
Body-mass index, kg/m2 28  6 28  3 27  5 0.91
Blood pressure, mm Hg
Systolic 138  14 140  35 136  15 0.94
Diastolic 79  5 80  5 79  6 0.21
Mean 90  6 90  5 89  6 0.20
Heart rate, beats/min 73  10 73  11 72  10 0.22
<60 6 (5) 2 (8) 4 (4) 0.60
Permanent pacemaker 6 (5) 2 (8) 4 (4) 0.53
Symptomatic carotid
artery disease
40 (32) 9 (34.5) 31 (31) 0.53
LV ejection fraction, % 54  10 48  10 53  10 0.33
Systemic hypertension 117 (93) 24 (92) 93 (93) 1.00
Hypercholesterolemia 82 (65) 14 (54) 68 (68) 0.25
Diabetes mellitus 55 (43.5) 14 (54) 41 (40.5) 0.29
Coronary artery disease 69 (55) 14 (54) 55 (55) 1.00
Contralateral carotid occlusion 17 (13.5) 2 (8) 15 (15) 0.35
Previous endarterectomy 5 (4) 1 (4) 4 (4) 1.00
Drugs
Beta-blockers 31 (24.5) 7 (27) 24 (24) 0.80
Statins 105 (83) 22 (84.5) 83 (83) 1.00
Serum creatinine, mg/dl 1.49 (1.30, 1.70) 1.54 (1.27, 1.73) 1.54 (1.32, 1.83) 0.53
eGFR, ml/min/1.73 m2 42  12 43  15 42  12 0.53
Anemia† 50 (40) 16 (61.5) 34 (34) 0.014
Contrast nephropathy risk score* 9  3 10  3 8  3 0.032
CIAKI, % 17  7 21  10 17  7 0.026
Dialysis, % 0.5  1.1 1.4  2.5 0.4  0.5 0.22
Volume of contrast media, ml 121  50 116  52 112  48 0.69
Contrast ratio >1 96 (77) 22 (85) 74 (74) 0.21
Prophylaxis
Sodium bicarbonate solution
and NAC
121 (96) 26 (100) 95 (95) 0.58
RenalGuard therapy 5 (4) 0 5 (5)
Values are mean  SD, n (%), or median (interquartile range). *According to Mehran et al. (17). †Anemia deﬁned
as baseline hematocrit <39% for male and <36% for female patients.
AKI ¼ acute kidney injury; CIAKI¼ contrast-induced acute kidney injury; eGFR ¼ estimated glomerular ﬁltration
rate; LV ¼ left ventricular; NAC ¼ N-acetylcysteine.
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1508weight divided by sCr (mg/dl). When the “contrast ra-
tio,” that is the dichotomous variable obtained by
dividing the actual amount of contrast received by the
calculated maximum contrast dose, was >1, then the
contrast dose was considered high (21).
STUDY OBJECTIVES. The outcome measures were as
follow: 1) the development of AKI, deﬁned as an in-
crease in sCr concentration $0.3 mg/dl at 48 h after
CAS or the need for dialysis (8); 2) the relationship
between AKI and both CM volume and hemodynamic
depression; and 3) the relationship between AKI and30-day MAE, deﬁned as death, stroke, and acute
myocardial infarction. The severity of AKI was
assessed according to the Acute Kidney Injury
Network criteria: stage 1, an sCr increase $0.3 mg/dl
or $1.5 to 1.9 from baseline; stage 2, an sCr
increase $2.0 to 2.9 from baseline; and stage 3, an
sCr increase $3.0 from baseline or the need for
dialysis (8). Myocardial infarction was diagnosed in
the occurrence of persistent ST-segment changes
and/or new Q waves in 2 leads or the presence of
elevated enzymes (including troponin >0.1 ng/ml).
Neurological complications were classiﬁed as being
among the following: 1) minor stroke, deﬁned as a
new neurological deﬁcit that either resolves com-
pletely within 30 days or increased NIHSS (National
Institute of Health Stroke Scale) by #3; and 2) major
stroke, deﬁned as a new neurological deﬁcit that
persists for >30 days and increased NIHSS by $4 (22).
Bleeding was deﬁned according to the Bleeding Aca-
demic Research Consortium criteria (23).
STATISTICAL ANALYSIS. Continuous variables are
given as mean  SD or median and interquartile
range (IQR), when appropriate. Student t test and
nonparametric Mann-Whitney tests were used to
determine differences between mean values for nor-
mally and, respectively, not normally distributed
variables. Categorical variables were reported as
percentages and were analyzed by either chi-squared
or Fisher exact tests, as appropriate. Receiver-
operating characteristic curve was generated, and
the area under the curve was calculated to evaluate
the time threshold of hemodynamic depression for
AKI development. Generalized linear model was
performed to determine whether contrast volume and
hemodynamic depression were independent pre-
dictors of AKI with and without adjustment for con-
founders selected according to the study hypothesis,
literature, and signiﬁcance (p < 0.1) at univariate
analysis. Hosmer-Lemeshow goodness-of-ﬁt test was
assessed. Survival curves were generated using
Kaplan-Meier analysis, and unadjusted comparisons
between groups were compared with log-rank test.
Cox proportional hazards model was used to provide
hazard ratios with 95% conﬁdence intervals (CI) and
adjustment for previously selected risk factors (the
same criteria reported herein). Potential interactions
due to the therapy were evaluated. To correct for
multiple testing, 200 bootstrap iterations were
computed. For all tests, p < 0.05 was considered
statistically signiﬁcant. All p values are 2-sided. Data
were analyzed with SPSS (version 13.0, SPSS, Inc.,
Chicago, Illinois) for Windows and Stata (version
11/SE, Stata Corp., College Station, Texas).
TABLE 2 Angiographic and Procedural Characteristics of the Global Population and of
Patients With Versus Those Without AKI
Global Population
(n ¼ 126)
AKI Group
(n ¼ 26)
Non-AKI Group
(n ¼ 100) p Value
Right internal carotid artery 71 (56%) 17 (65%) 54 (54%) 0.18
Left internal carotid artery 55 (44) 9 (35) 46 (46)
Eccentric 89 (72.5) 21 (80) 68 (68) 0.14
Ulceration 18 (14) 6 (23) 12 (12) 0.14
Calciﬁcation 29 (23) 5 (19) 24 (24) 0.60
Involvement of the bulb 72 (57) 14 (53) 58 (58) 0.95
Reference vessel diameter, mm 6.03  0.77 6.06  0.59 5.94  0.77 0.59
Minimal lumen diameter, mm 1.57  0.79 1.71  0.03 1.54  0.75 0.45
Diameter stenosis, % 77  12 74  15 78  12 0.64
Pre-dilation 9 (7) 4 (15) 5 (5) 0.086
Post-dilation 126 (100) 26 (100) 100 (100) 1.00
Balloon diameter 5.32  0.38 5.30  0.35 5.34  0.35 0.72
Balloon-to-artery ratio 0.90  0.12 0.89  0.10 0.92  0.12 0.61
Stent diameter, mm 9.36  0.96 9.68  0.69 9.27  0.97 0.022
Stent length, mm 37  4 37  4 37  4 0.72
Maximal inﬂation pressure, atm 14  3 14  2 14  3 0.18
Stent-to-vessel ratio 1.55  0.17 1.58  0.17 1.54  0.26 0.77
Stent type 0.21
Wallstent 22 (17.5) 1 (3.8) 21 (21)
Acculink 31 (24.5) 7 (27) 24 (24)
Protegè 42 (33) 11 (42) 31 (31)
Sinus Carotid RX 8 (6) 2 (7.7) 6 (6)
Crystallo Ideale 10 (8) 4 (15.5) 6 (6)
Precise 12 (9.5) 1 (3.8) 11 (11)
X-Act 1 (0.8) 0 1 (1)
Braided Elgiloy 22 (17.5) 1 (4) 21 (21) 0.044
Nitinol 104 (82.5) 25 (96) 79 (79)
Closed cell 23 (18) 1 (4) 22 (20) 0.13
Open cell 85 (67.5) 19 (73) 66 (66)
Hybrid cell 18 (14.5) 6 (23) 12 (12)
Protection device 0.41
SpideRX* 74 (59) 19 (73) 55 (55)
Emboshield† 14 (11) 2 (7.7) 12 (12)
EPI ﬁlter‡ 21 (16.5) 2 (7.7) 19 (19)
RX Accunet† 2 (1.5) 1 (3.8) 1 (1)
Angioguard RX§ 11 (9) 1 (3.8) 10 (10)
Mo.Mak 4 (3) 1 (3.8) 3 (3)
Values are n (%) and mean  SD. *SpideRX (Covidien, Mansﬁeld, Massachusetts). †Emboshield and RX Accunet
(Abbott Vascular Devices, Redwood City, California). ‡EPI ﬁlter (Boston Scientiﬁc, Natick, Massachusetts).
§Angioguard RX (Cordis, Miami Lakes, Florida). kMo.Ma (Medtronic Inc., Minneapolis, Minnesota).
AKI ¼ acute kidney injury.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 1 , 2 0 1 5 Donahue et al.
S E P T E M B E R 2 0 1 5 : 1 5 0 6 – 1 4 Acute Kidney Injury After Carotid Stenting
1509RESULTS
PATIENTS POPULATION. This study included 126
CKD patients (Table 1). Forty patients (32%) were
symptomatic for carotid artery disease. Mean arterial
pressure was 90  6 mm Hg. Mean heart rate was 73 
10 beats/min, and 6 patients (4.8%) were bradycardic
before the procedure.
CAROTID ARTERY STENTING PROCEDURE. Balloon pre-
dilation was required in 9 patients (7%). The type
of embolic protection device and self-expandable
stent are reported in the Table 2. The procedure was
technically successful in all patients. Hemodynamic
depression occurred in 52 of 126 patients (41%) and
was persistent in 15 of 126 patients (12%). Hemody-
namic depression, which occurred in all instances
during or following post-dilation, was due to hypo-
tension alone in 46 of 52 patients (88.5%), bradycardia
alone in 2 patients (4%), and both hypotension and
bradycardia in 4 patients (7.5%). Vasopressor treat-
ment was accomplished in 35 of these 52 patients
(67%). Median duration of hemodynamic depression
was 4 (interquartile range: 0, 556) min. Characteristics
of patients with and without hemodynamic depres-
sion are reported in the Table 3. Patients with hemo-
dynamic depression more often had lesions involving
the bulb and smaller vessel size and less often had
previous endarterectomy. Furthermore, patients with
hemodynamic depression were more often treated
with nitinol and open-cells stents (Table 3).
AKI. AKI occurred in 26 patients (21%) (Tables 1 and 2).
The majority of these patients (21 of 26 [81%])
experienced a stage 1 AKI, and only 5 of 26 (19%) had
a stage 2 AKI. Patients in the AKI group were more
often male, active smokers, anemic, and had a high
Mehran risk score. Balloon pre-dilation was more
frequent (15% vs. 5%; p ¼ 0.086) and mean stent
diameter was larger (9.68  0.69 vs. 9.36  0.96; p ¼
0.022) in the AKI group. Furthermore, the implanta-
tion of a nitinol stent was more frequent in the AKI
group (96% vs. 79%; p ¼ 0.044). Baseline eGFR, CM
volume, and prophylactic strategies for contrast-
induced AKI were similar in the AKI and non-AKI
groups (Table 1). Changes in intraprocedural systolic
and mean blood pressure in AKI and non-AKI groups
are represented in Figure 1. Hemodynamic depression
occurred in 17 of 26 patients (65.5%) in the AKI group
versus 35 of 100 patients (35%) in the non-AKI group
(odds ratio [OR]: 3.50; 95% CI: 1.42 to 8.68; p ¼ 0.005).
Similarly, persistent hemodynamic depression was
more common in the AKI group (10 of 26 [38.5%] vs. 5
of 100 [5%]; OR: 11.87; 95% CI: 3.59 to 39.31; p < 0.001).
Median duration of hemodynamic depression waslonger in the AKI group than non-AKI group (630 [IQR:
0 to 1440] vs. 3 [IQR: 0 to 4.5] min; p < 0.001). A sig-
niﬁcant positive correlation was observed between
duration of hemodynamic depression and absolute
difference of serum creatinine between post-
procedural and baseline values (r ¼ 0.55; p < 0.001)
(Figure 2). By receiver-operating characteristic anal-
ysis, 2.5 min was the threshold of hemodynamic
depression duration (54% sensitivity and 82% speci-
ﬁcity) for AKI development (Figure 3). Vasopressor
treatment was more common in the AKI group (13 of
TABLE 3 Characteristics of Patients With Versus Those Without Hemodynamic
Depression
Hemodynamic
Depression Group
(n ¼ 52)
Non–Hemodynamic
Depression Group
(n ¼ 74) p Value
Age, yrs 76  7 76  7 0.80
Male 37 (71) 58 (78) 0.26
Blood pressure, mm Hg
Systolic 137  16 134  14 0.39
Diastolic 79  5 78  6 0.68
Mean 90  6 90  6 0.49
Heart rate, beats/min 74  9 71  11 0.19
<60 2 (4) 4 (5) 0.60
Permanent pacemaker 2 (4) 4 (5) 0.60
LV ejection fraction, % 52  12 55  9 0.51
Diabetes mellitus 19 (36.5) 26 (35) 1.00
Contralateral carotid occlusion 10 (20) 7 (9.5) 0.18
Previous endarterectomy 0 5 (6.5) 0.041
Beta-blockers 13 (26) 18 (24) 0.96
eGFR, ml/min/1.73 m2 42  12 42  12 0.87
Contrast nephropathy risk score* 9  4 9  3 0.77
Volume of contrast media, ml 118  48 109  49 0.31
Contrast ratio >1 41 (79.5) 55 (74.5) 0.73
Reference vessel diameter, mm 5.85  0.64 6.17  0.84 0.066
Diameter stenosis, % 75  13 79  12 0.15
Pre-dilation 5 (9.5) 4 (5.5) 0.48
Post-dilation 52 (100) 74 (100) 1.00
Balloon diameter 5.28  0.41 5.35  0.36 0.074
Balloon-to-artery ratio 0.92  0.10 0.89  0.13 0.28
Stent diameter, mm 9.39  0.98 9.33  0.96 0.74
Stent length, mm 38  4 37  5 0.49
Maximal inﬂation pressure, atm 14  2 15  3 0.18
Stent-to-vessel ratio 1.59  0.27 1.52  0.27 0.28
Eccentric 38 (73) 51 (69) 0.69
Calciﬁcation 10 (19) 19 (26) 0.34
Involvement of the bulb 38 (74) 34 (45) 0.003
Stent type 0.099
Wallstent 3 (5.5) 19 (25.5)
Acculink 13 (25) 18 (24.5)
Protegè 22 (42.5) 20 (27)
Sinus Carotid RX 4 (7.7) 4 (5.5)
Crystallo Ideale 4 (7.7) 6 (8)
Precise 6 (11.5) 6 (8)
X-Act 0 1 (1.5)
Braided Elgiloy 3 (5.5) 19 (25.5) 0.002
Nitinol 49 (94.5) 55 (74.5)
Closed cell 3 (5.5) 20 (27) 0.015
Open cell 41 (79) 44 (59.5)
Hybrid cell 8 (15.5) 10 (13.5)
Values are mean  SD or n (%). *According to Mehran et al. (17).
Abbreviations as in Table 1.
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151026 [50%] vs. 22 of 100 patients [22%]; p ¼ 0.007). In-
dependent predictors of AKI were hemodynamic
depression (OR: 4.01; 95% CI: 1.07 to 15.03; p ¼ 0.009),
risk score (OR: 1.29; 95% CI: 1.03 to 1.60; p ¼ 0.024),
and male sex (OR: 6.07; 95% CI: 1.18 to 31.08;
p ¼ 0.021) (Table 4).IN-HOSPITAL AND 30-DAY MAE. In-hospital and
30-day MAE occurred in 12 patients (9.5%) and were
more common in the AKI group than in the non-AKI
group (5 of 26 [19.5%] vs. 7 of 100 [7%]; OR: 6.39;
95% CI: 1.01 to 40.48; p ¼ 0.058) (Table 5, Figure 4).
The higher MAE events rate in the AKI group was
driven by the higher death rate (3 of 26 [11.5%] vs. 2
of 100 [2%]; p ¼ 0.026), whereas the rate of neuro-
logical complication was similar in the 2 groups
(Table 5). Major bleeding occurred in 1 patient in the
AKI group (3.8%) and in none in the non-AKI group
(p ¼ 0.21). Independent predictors of 30-day MAE
were AKI (HR: 4.83; 95% CI: 1.10 to 21.24; p ¼ 0.037)
and hemodynamic depression (HR: 5.58; 95% CI:
1.10 to 28.31; p ¼ 0.038) (Table 6). Hemodynamic
depression $2.5 min occurred in 5 of 12 patients
(41.5%) with MAE and in 14 of 114 patients (12.5%)
without MAE (OR: 5.01; 95% CI: 1.42 to 18.29;
p ¼ 0.019).
DISCUSSION
Themain results of the current study addressing AKI in
CKD patients undergoing CAS are as follow: 1) AKI rate
is higher than expected; 2) hemodynamic depression
(mostly due to hypotension), but not CM volume,
represents an independent predictor of AKI; and 3) AKI
is associated with a higher 30-day MAE rate.
AKI FOLLOWING CAS. The observed AKI rate (21%)
was higher than expected. The reported low (<1%)
contrast-induced AKI in previous studies may be
explained by the following: 1) CAS is generally avoi-
ded in patients with severe renal dysfunction (14),
and/or 2) AKI is under-reported. In our population,
according to the Mehran risk score (17), the predicted
risk for contrast-induced AKI was approximately 17%.
This risk score, although developed in patients un-
dergoing CM exposure for coronary interventions, is
an independent predictor of AKI even in CKD patients
undergoing CAS.
PATHOPHYSIOLOGY OF AKI AFTER CAS. Our results
suggest a prevalent role of hemodynamic depression
in the pathophysiology of AKI following CAS. The lack
of signiﬁcant differences in both traditional risk fac-
tors for AKI (i.e., baseline eGFR, diabetes mellitus,
age, contrast media volume) and the Mehran risk
score between patients with versus those without
hemodynamic depression reinforces the indepen-
dent role of hemodynamic depression in the patho-
physiology of AKI in this clinical setting.
Hemodynamic depression after CAS almost always
was due to hypotension (alone and/or associated
to bradycardia). This results from baroreceptor
FIGURE 1 Systolic and Mean Blood Pressure in Patients With and Without AKI
Systolic (A) and mean blood pressure (B) before, during, and after the procedure in patients with (solid line) and without (dashed line) acute
kidney injury (AKI). Post hoc test adjusted p value was assessed by repeated measures analysis of variance model.
FIGURE 2 Relationship Between Duration of Hemodynamic Depression and Absolute
Change in sCr Levels
Relationship between duration of hemodynamic depression (minutes) and absolute change
in serum creatinine (sCr) levels from baseline to peak value after contrast media exposure.
Open circles represent patient without acute kidney injury (AKI); closed circles represent
patients with AKI.
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1511stimulation that occurs particularly at the time of
balloon inﬂation in the region of the carotid sinus
(24). Furthermore, nitinol stents are associated with a
higher risk of hemodynamic depression. This ﬁnding
might be explained by their higher outward radial
expansion force than that of the braided Elgiloy
stents, thereby exerting higher pressure on the ca-
rotid sinus. Given that the carotid sinus has its main
role in short-term blood pressure regulations, this
ﬁnding might be explained by continuing post-
deployment expansion of self-expanding stents (25).
Hemodynamic depression has been associated with
an increased risk of developing major periprocedural
adverse clinical events, including death and stroke
(9,26). In the CAS arm of the CREST (Carotid Revas-
cularization Endarterectomy Versus Stenting Trial),
patients who had stroke more often experienced he-
modynamic depression requiring treatment (27,28).
Intraoperative hemodynamic depression has the
potential to cause an ischemia-reperfusion injury,
which, in turn, may substantially contribute to post-
operative AKI (13). The putative major mechanism of
peri-operative AKI is a decrease in kidney perfusion
with associated ischemia and activation of inﬂam-
matory mediators, adhesion molecules, platelets, and
thromboxane (29,30). It has been demonstrated an
independent, graded relationship between the length
of time spent with a mean blood pressure <55 mm Hg
(13) or <60 mm Hg (31) and AKI. Furthermore, the
longer the time with a mean blood pressure <55
FIGURE 3 ROC Curves of Duration of Hemodynamic
Depression for AKI Diagnosis
Receiver-operating characteristic (ROC) curves of duration of
hemodynamic depression (min) for the diagnosis of acute kidney
injury (AKI). AUC ¼ area under the curve.
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1512mm Hg, the higher the risk of 30-day death after
surgery (13). In the current study, we identiﬁed 2.5
min as the threshold of hemodynamic depression
duration with a 54% sensitivity and 82% speciﬁcity
for AKI development (Figure 3). In healthy animals,
renal blood ﬂow is maintained (autoregulated) down
to a mean blood pressure <70 mm Hg (32). It may be,
however, that in CKD patients the autoregulation
pathway becomes impaired. As such, optimizing peri-
operative hemodynamics may mitigate or prevent
this complication. This theory is supported by theTABLE 4 Independent Predictors of AKI
Multivariable Analysis
OR 95% CI p Value
Bootstrap
p Value*
Hemodynamic
depression
4.01 1.07–15.03 0.009 0.039
Risk score 1.29 1.03–1.60 0.024 0.034
Male 6.07 1.18–31.18 0.021 0.030
Stent diameter 1.71 0.66–4.38 0.129 0.262
Nitinol stent 0.23 0.04–1.33 0.199 0.101
Pre-dilation 2.73 0.39–18.76 0.267 0.308
eGFR 1.02 0.93–1.11 0.381 0.381
Contrast media volume 0.99 0.98–1.01 0.738 0.637
*For the adjusted p values, bootstrap sampling method (200 repetitions) was
employed. Hosmer-Lemeshow goodness-of-ﬁt p ¼ 0.71.
CI ¼ conﬁdence interval; eGFR¼ estimated glomerular ﬁltration rate; OR ¼ odds
ratio.observation that strategies preventing peri-operative
hypotension are effective in reducing the incidence
of AKI (33). Although we adopted the systematic use
of atropine before balloon post-dilation, the rate of
hemodynamic depression is still high. Additional
strategies, therefore, should be implemented to pre-
vent this complication in CKD patients.
Unlike coronary interventions, the impact of CM
seems to be attenuated in CAS, due to the dominant
role of hemodynamic depression (17,34). Our data
may be interpreted in the following ways: 1) by the
limited power of the study (due to the small sample
size) to ﬁnd signiﬁcant difference in contrast volume
between the AKI and non-AKI groups; 2) by taking
into account the systematic adoption of the recom-
mended prophylactic strategies to prevent CM-
induced kidney damage, and the systematic use of
atropine to prevent hemodynamic depression; and 3)
by the possibility that hemodynamic depression may
increase the nephrotoxic potential of CM. Hemody-
namic depression, by impairing renal circulation, may
prolong the time for CM elimination and, therefore,
increase the risk of CM-induced tubular epithelial
cells apoptosis (20). The high AKI rate observed in the
present study may support this hypothesis.
AKI AND PROGNOSIS IN CKD PATIENTS UNDERGOING
CAS. CKD has been well described as an independent
predictor of mortality in patients undergoing
vascular operations (35) and coronary artery re-
vascularizations (36). Controversies still exist on the
prognostic association between CKD and both surgi-
cal and percutaneous revascularization for carotid
artery stenosis (2,3,7). Possible explanations are the
limited data available on CKD patients enrolled in the
major trials and the lack of systematic evaluation of
post-procedural AKI. Indeed, no data on CKD patients
have been reported in several trials (27,37–39). In the
SAPPHIRE (Stenting and Angioplasty with Protection
in Patients at High Risk for Endarterectomy) trial (40),
only 6% of patients in the CAS arm had CKD. The most
important data comes from the CARE (Carotid Artery
Revascularization and Endarterectomy) registry (2),
where CKD occurred in 37.5% of patients. The ma-
jority (63%) of these CKD patients underwent CAS.
Although patients with CKD treated by CAS had worse
unadjusted in-hospital and 30-day outcomes (mainly
driven by higher stroke rates), this association was no
longer signiﬁcant after adjustment for patients’
baseline characteristics (2). Indeed, worse kidney
function was associated with older age and a signiﬁ-
cantly higher prevalence of comorbidities. Therefore,
it has been proposed that CKD may only be a marker
for more advanced disease and more comorbidities
TABLE 5 MAE at 1 Month in the Global Population and
in Patients With Versus Those Without AKI
Global
Population
(n ¼ 126)
AKI
Group
(n ¼ 26)
Non-AKI
Group
(n ¼ 100)
p
Value
Cumulative MAE 12 (9.5) 5 (19.5) 7 (7) 0.058
Death 5 (4) 3 (11.5) 2 (2) 0.026
Any neurological
complication
7 (5.5) 2 (7.6) 5 (6.5) 0.63
Minor stroke 6 (4.8) 1 (3.8) 5 (5) 0.045
Major stroke 1 (0.7) 1 (3.8) 0 0.58
Myocardial infarction 0 0 0 —
Values are n (%).
AKI ¼ acute kidney injury; MAE ¼ major adverse events.
TABLE 6 Independent Predictors of 30-Day MAE
Multivariable Analysis
HR 95% CI p Value*
AKI 4.83 1.10–21.24 0.037
Hemodynamic depression 5.58 1.10–28.31 0.038
eGFR 1.06 1.00–1.12 0.061
Age 1.12 0.99–1.26 0.071
Male 0.42 0.09–1.92 0.263
*For the adjusted p values, bootstrap sampling method (200 reps) was employed.
Hosmer-Lemeshow goodness-of-ﬁt p ¼ 0.44.
HR ¼ hazard ratio; other abbreviations as in Tables 1, 4, and 5.
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1513(3). The present study suggests another possible
explanation: the unfavorable prognosis following CAS
is mostly limited to CKD patients experiencing post-
procedural AKI. Further studies, however, are
needed to test whether strategies preventing AKI may
improve outcomes following CAS in CKD patients.
STUDY LIMITATIONS. This is a single-center, obser-
vational study, with the intrinsic shortcoming of
potentially limited external validity and intrinsic
bias. The small sample size represents a further
limitation. Although hypotension is recognized as
an important factor in the development of post-
operative complications, there is uncertainty in how
to optimally deﬁne intraoperative hypotension (41).
In a clinical perspective, the low sensitivity of
hemodynamic depression time represents an impor-
tant limitation. Indeed, given the short thresholdFIGURE 4 Kaplan-Meier Curves of 30-Day MAE in Patients
With and Without AKI
Kaplan-Meier curves of 30-day major adverse events (MAE) in
patients with (continuous line) and without (dotted line) acute
kidney injury (AKI). Unadjusted log rank p value ¼ 0.0039.time, a high sensitivity would have been a more
clinically useful marker. However, the observed
graded relationship between the length of time spent
with hemodynamic depression and AKI highlights the
importance of limit hemodynamic depression time as
much as possible (13). The present results refer only
to patients with CKD. Additional studies are needed
to assess the role of hemodynamic depression and CM
volume in the occurrence of AKI and MAE in non-CKD
patients undergoing CAS.
CONCLUSIONS
The current study addressing AKI in CKD patients
undergoing CAS suggests the following: 1) AKI rate
is higher than expected; 2) hemodynamic depres-
sion (mostly due to hypotension) but not CM vol-
ume represents an independent predictor of AKI;
and 3) AKI is associated with a higher 30-day MAE
rate.
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WHAT IS KNOWN? AKI following CAS may occur because of
iodinated CM and hemodynamic depression.
WHAT IS NEW? In CKD patients, undergoing CAS, hemodynamic
depression but not CM volume represents an independent pre-
dictor of AKI, and AKI is associated with a higher 30-day MAE rate.
WHAT IS NEXT? Further studies are needed to assess whether
preventing hemodynamic depression will reduce the AKI rate and
therefore improve outcome following CAS.
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